Trial Profile
Prospective Evaluation of -1498 c/t VEGF Polymorphism in the Prediction of Benefit From First-line Folfiri Plus Bevacizumab in Metastatic Colorectal Cancer Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms PROVETTA
- 10 Aug 2015 New trial record